News | Loda Lab

Lipids and DNA damage in prostate cancer - paper alert!

April 18, 2024

Androgen deprivation therapy (ADT) is the primary treatment for prostate cancer, but resistance often develops, leading to CRPC. FASN, the main enzyme of de novo lipogenesis, is overexpressed in prostate cancer cells, and drives the synthesis of fatty acids, fueling cancer growth. Our newest publication, “Blocking lipid synthesis induces DNA damage in prostate cancer and increases cell death caused...

Loda Lab participates at the AACR 2024 Annual Meeting

April 16, 2024

Researchers from the Loda Lab made a significant impact at the 2024 Annual Meeting of the American Association for Cancer Research (AACR), held in San Diego (US). The team not only presented cutting-edge research, but also engaged in valuable networking with fellow scientists.

The AACR Annual Meeting is one of the largest and most influential gatherings in the field, dedicated to advancing cancer research to benefit patients. "Our participation at AACR 2024 allowed us to share...

Dr. Pederzoli elected to the Associate Member Council of the AACR

March 19, 2024

Dr. Filippo Pederzoli has been elected to the Associate Member Council of the American Association for Cancer Research (AACR).

The Associate Member Council represents the leadership body of the AACR's Associate Members, who are made up of graduate students, medical students and residents, and clinical and postdoctoral fellows enrolled in educational or training programs leading to careers in cancer research anywhere in the world. The Council helps develop and...

1 of 4
next ›